Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study

the AMAF investigators

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences